Glaucome néovasculaire et traitement anti-angiogénique
| Autor: | O. Laplace |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
genetic structures Bevacizumab medicine.medical_treatment VEGF receptors Neovascular glaucoma Neovascularization chemistry.chemical_compound Ophthalmology medicine Intravitreal bevacizumab Chemotherapy biology business.industry Macular degeneration medicine.disease eye diseases Surgery Vascular endothelial growth factor chemistry biology.protein sense organs medicine.symptom business medicine.drug |
| Zdroj: | Journal Français d'Ophtalmologie. 32:230-235 |
| ISSN: | 0181-5512 |
| Popis: | Recent research has shown the key role of vascular endothelial growth factor (VEGF), mainly one of its isoform, VEGF-A, in ocular pathologies involving neovascularization. New intraocular treatments targeting specifically VEGF (anti-VEGF) has been developed. These agents have revolutionized the treatment and visual prognosis of neovascular agerelated macular degeneration (AMD). Their potential for other ocular diseases, such as neovascular glaucoma, is currently under clinical investigations. We briefly review the current knowledge and clinical data, and present our clinical experience with the use of intravitreal bevacizumab in neovascular glaucoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|